|
PLEKHF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.94569999947925E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.92869999996004E-06 |
| Normal-vs-Stage2 |
2.08010000002368E-06 |
| Normal-vs-Stage3 |
4.62610000306896E-08 |
| Normal-vs-Stage4 |
1.45719999955496E-07 |
| Stage1-vs-Stage2 |
2.064400E-01 |
| Stage1-vs-Stage3 |
2.495900E-02 |
| Stage1-vs-Stage4 |
2.450300E-02 |
| Stage2-vs-Stage3 |
7.366200E-01 |
| Stage2-vs-Stage4 |
4.843200E-01 |
| Stage3-vs-Stage4 |
5.944400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.0828000003621E-07 |
| Normal-vs-AfricanAmerican |
9.414600E-04 |
| Normal-vs-Asian |
2.40640000004344E-06 |
| Caucasian-vs-AfricanAmerican |
8.898000E-01 |
| Caucasian-vs-Asian |
8.484800E-01 |
| AfricanAmerican-vs-Asian |
9.995000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.10839999961843E-07 |
| Normal-vs-Female |
5.02070000019117E-07 |
| Male-vs-Female |
4.876200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64869000000012E-05 |
| Normal-vs-Age(41-60Yrs) |
9.24249999867399E-08 |
| Normal-vs-Age(61-80Yrs) |
6.58369999628761E-08 |
| Normal-vs-Age(81-100Yrs) |
5.686500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.642000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.449390E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.906600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.132200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.360000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.258200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.117760E-02 |
| Classical-VS-Follicular |
5.223300E-03 |
| Classical-VS-Other |
4.150400E-01 |
| Classical-VS-Normal |
1.78927999999745E-05 |
| Tall-VS-Follicular |
4.952600E-01 |
| Tall-VS-Other |
7.308000E-01 |
| Tall-VS-Normal |
3.87309999627661E-08 |
| Follicular-VS-Other |
9.177400E-01 |
| Follicular-VS-Normal |
4.95549999923739E-08 |
| Other-VS-Normal |
2.252200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.02119999959116E-07 |
| Normal-vs-N1 |
5.46519995925365E-09 |
| N0-vs-N1 |
6.620300E-02 |
|
|
